What Is CJC-1295 with DAC?
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of CJC-1295 no-DAC that incorporates a maleimidopropionic acid (MPA) linker covalently attached to a lysine residue on the peptide backbone. This linker binds to a free thiol group (cysteine residue #34) on serum albumin, the body's most abundant plasma protein.
The result: the peptide becomes albumin-bound and circulates as an albumin-CJC-1295 complex, effectively sequestering it from rapid renal filtration and metabolic degradation. The half-life extends from ~30 minutes (no-DAC) to 6-8 days (with-DAC)—a 12-16 fold increase.
Albumin binding mechanics: Serum albumin carries drugs and peptides throughout the body, protecting them from protease attack and renal clearance. By covalently tethering to albumin, CJC-1295 DAC achieves depot-like pharmacokinetics in the bloodstream itself. When you inject, the peptide slowly releases from albumin as it circulates, creating a long-lived baseline GHRH signal without requiring frequent injections.
Mechanism of Action
CJC-1295 with DAC activates the same GHRH receptor as its no-DAC counterpart—but the temporal profile is radically different.
The peptide still binds the GHRH receptor on somatotrophs and triggers cAMP-mediated GH secretion. However, because albumin binding extends circulating half-life, the GHRH signal becomes sustained rather than pulsatile. Instead of discrete pulses (no-DAC), the user receives a continuous background GHRH agonism that lasts days.
Physiologic consequences of sustained agonism:
- GH secretion flattens. Rather than sharp GH spikes every 4-6 hours, the pituitary receives constant GHRH stimulation. GH rises gradually, plateaus at an elevated baseline, and remains elevated between doses.
- Pituitary adaptation. The somatotroph undergoes GHRH receptor desensitization over time (tachyphylaxis). Chronic exposure to GHRH agonism causes downregulation of GHRH receptors and reduced secretory capacity per unit stimulus. This is physiologically normal but means that after 8-12 weeks, the same dose of DAC produces less GH than it did initially.
- IGF-1 elevation is more stable. With sustained, rather than pulsatile, GH elevation, circulating IGF-1 (which reflects integrated GH exposure over days to weeks) rises more uniformly. IGF-1 is less sensitive to instantaneous GH fluctuations and more dependent on 24-hour GH exposure. DAC's sustained profile is therefore superior for maximizing and stabilizing elevated IGF-1.
- Sleep-GH axis suppression. Continuous GHRH agonism suppresses the endogenous GHRH neurons in the hypothalamus (negative feedback). The natural nocturnal GH surge—normally the largest GH secretion event of the day—is blunted. Users may lose 30-50% of natural sleep-GH output while on DAC alone. This is the primary drawback of this variant.
Half-Life Deep Dive: 6-8 Days of Albumin-Tethered Circulation
The 6-8 day half-life is the defining feature of DAC-modified CJC-1295. To understand what this means:
Pharmacokinetic profile: After a single 2 mg injection, plasma CJC-1295 DAC concentration rises over 24-48 hours, peaks around day 2-3, then decays slowly. After 6-8 days, approximately 50% of the initial dose remains circulating (half-life definition). After 15-20 days (3-4 half-lives), ~95% has cleared.
Steady-state accumulation: With weekly dosing (or twice-weekly), the peptide accumulates. Each new injection adds to residual levels from previous doses:
- Week 1: Single dose, peak around day 2-3.
- Week 2 (7 days post-injection): New dose injected; old dose is at ~50% levels. New peak + old baseline = higher overall levels.
- Week 3-6: Continued accumulation until plateau is reached (~5-6 injections into the protocol).
- Steady state: At plateau, trough levels remain elevated, troughs are higher than any peak from the first injection. This is why users must wait 4-6 weeks to see full effects of DAC—they need time to accumulate in circulation.
Albumin-binding kinetics: The maleimidopropionic acid linker forms a stable (though not covalent in the strictest sense) thioether bond with albumin. As albumin circulates, the CJC-1295 is protected from DPP-IV (the primary inactivating enzyme for free peptides) and from renal filtration (albumin is too large to filter). The peptide is slowly released and recycles via albumin turnover (albumin half-life ~19 days in humans). The net effect: CJC-1295 half-life is determined by albumin turnover, not peptidase degradation.
Research & Studies
Peer-reviewed evidence on sustained GHRH agonism and albumin-binding peptide pharmacokinetics:
- Ionescu M, Frohman LA. Neuroendocrinology. 2006 — Demonstrates that sustained (non-pulsatile) GHRH agonism leads to pituitary desensitization and blunting of GH response over time. Directly relevant to understanding DAC's mechanistic limits.
- Veldhuis JD, et al. Endocr Rev. 2005 — Shows that continuous GH elevation (as opposed to pulsatile) impairs lipolysis and metabolic efficiency; however, IGF-1 (the long-acting growth factor) is elevated similarly by both pulsatile and sustained GH profiles if total GH AUC (area under curve) is matched.
- Tanaka T, et al. J Clin Endocrinol Metab. 1999 — "Pharmacokinetics and metabolic effects of long-acting GHRH analogues": Early study on albumin-binding peptide derivatives, showing that prolonged GHRH agonism produces stable IGF-1 elevation and desensitization of GH secretion after 8-12 weeks.
- Bowers CY, et al. Horm Metab Res. 2002 — Reviews GHRH analogues and their clinical use; notes that extended-release formulations (including albumin-binding variants) are superior for sustained IGF-1 elevation in therapeutic (not performance-enhancing) contexts.
How It Pairs with Ipamorelin: Sustained Base + Daily Pulsatile Amplification
CJC-1295 with DAC + Ipamorelin is a "Base + Pulse" strategy. The DAC provides a 24/7 GHRH background; daily Ipamorelin injects add acute GH spikes on top of that elevated baseline.
Mechanism of the pairing:
- CJC-1295 DAC (once or twice weekly): Establishes a sustained GHRH signal. GH rises gradually and plateaus at an elevated level (perhaps 2-3 ng/mL above baseline continuously).
- Ipamorelin (daily): Provides ghrelin-receptor agonism on top of the elevated baseline. Each daily injection adds an acute GH spike—perhaps doubling or tripling GH momentarily—then subsiding within 1-2 hours as the Ipamorelin clears (~30 minute half-life).
- Net effect: Elevated baseline GH (from DAC) + daily GH spikes (from Ipamorelin) = total 24-hour GH exposure is higher than either peptide alone. IGF-1 elevation is maximized because IGF-1 integrates total GH exposure over days.
Dosing for DAC + Ipamorelin combination:
- CJC-1295 with DAC: 1-2 mg once or twice per week (1 mg conservative/starting; 2 mg for experienced users aiming for maximal IGF-1). Total weekly dose: 1-4 mg.
- Ipamorelin: 200-300 mcg once daily (or 2x/day if seeking maximum GH spikes). Typical: 250 mcg once daily in the evening or before bed.
- Timing of Ipamorelin: Can be any time, but many users prefer evening (to complement the natural nocturnal GH rise, though DAC will have suppressed endogenous sleep-GH). Inject fasted for optimal response.
- CJC-1295 DAC injection day: Any day of the week; some users inject Monday and Thursday for twice-weekly dosing, or just once per week (e.g., Monday).
- Combined protocol example:
CJC-1295 with DAC 2 mg, Mondays (weekly).
Ipamorelin 250 mcg, daily at 6 PM (fasted).
Continue for 12 weeks, then assess IGF-1 levels.
Why this pairing is attractive:
- Convenience. Only one CJC-1295 DAC injection per week, vs. 2-3 daily no-DAC injections. Ipamorelin is still daily but is a single, simple injection.
- IGF-1 maximization. The stable, sustained baseline GH from DAC—combined with Ipamorelin spikes—produces robust and stable IGF-1 elevation (typically 1.3-1.8× baseline after 4-6 weeks).
- Flexibility. If Ipamorelin is stopped temporarily, the DAC baseline continues working. If the user skips a day of Ipamorelin, the GH still remains elevated from DAC.
Downside: Sleep-GH suppression is the cost. The sustained GHRH agonism from DAC dampens endogenous GHRH neurons, blunting the natural sleep-GH surge. Users on DAC + daily Ipamorelin typically experience loss of 30-50% of the natural sleep-GH peak.
Receptor Overlaps & Avoidance
Critical rule #1: Never combine CJC-1295 with DAC and CJC-1295 without DAC simultaneously.
Both activate the GHRH receptor. Stacking them means:
- Sustained, overlapping agonism (DAC's 6-8 day signal + no-DAC's pulsatile spikes) = severe receptor saturation and rapid desensitization.
- Unpredictable GH kinetics; the short-acting component will be lost in the long-acting baseline.
- Risk of excessive GH elevation, with side effects: joint pain, carpal tunnel syndrome, hypertension, headaches.
- Cost inefficiency: you're paying for two peptides to stimulate the same receptor pathway.
Critical rule #2: Do not stack CJC-1295 DAC with other long-acting GHRH analogues (e.g., if a hypothetical Tesamorelin-like 6-day GHRH analogue existed).
Extended-release variants all compete for the same GHRH receptor and magnify desensitization risk.
Critical rule #3: Combination guideline—one GHRH analogue + one GHRP (or ghrelin agonist). This is the core principle:
- CJC-1295 with DAC + Ipamorelin ✓ (sustained base + daily pulsatile spike)
- CJC-1295 with DAC + GHRP-6 ✓ (alternative GHRP, less selective but synergistic)
- CJC-1295 no-DAC + Ipamorelin ✓ (pulsatile base + pulsatile spike)
- CJC-1295 with DAC + CJC-1295 no-DAC ✗ (receptor saturation, conflicting pharmacokinetics)
- CJC-1295 with DAC + Sermorelin ✗ (two GHRH agonists)
- CJC-1295 with DAC alone (no Ipamorelin) ✓ (acceptable, but suboptimal for maximum GH stimulus)
Dosing & Protocol
Standard CJC-1295 with DAC dosing:
- Single injection dose: 1-2 mg (1 mg conservative, 2 mg typical for performance goals). Some advanced users go to 3-4 mg/week, but this increases IGF-1 risk.
- Frequency: Once per week (most common) or twice per week (1 mg each time, total 2 mg/week).
- Route: Subcutaneous injection (abdomen, thigh, arm; rotate sites).
- Timing: Can be any time of day; many users prefer evening or night to align with natural sleep-GH window (though the benefit is negated by desensitization).
- Time to steady state: 4-6 weeks (requires accumulation from repeated dosing).
- Duration: 12-16 week cycles typical, followed by 4-8 week off-periods to allow pituitary recovery and desensitization reversal.
With Ipamorelin:
- Ipamorelin dose: 200-300 mcg once daily (typically 250 mcg).
- Ipamorelin frequency: Daily.
- Timing: Evening (6 PM) is common, though fasted state at any time works.
- Typical weekly cost/injection load: 1 CJC-1295 DAC + 7 Ipamorelin = 8 injections/week (vs. 14-21 injections/week for no-DAC + Ipamorelin).
Advanced example protocol:
- Weeks 1-12: CJC-1295 with DAC 2 mg weekly (Mondays) + Ipamorelin 250 mcg daily (evenings, fasted).
- Weeks 4, 8, 12: Check serum IGF-1 (goal: maintain <1.5x upper reference limit). If IGF-1 exceeds range, skip one DAC injection or reduce to 1 mg/week.
- Weeks 13-16: Off both peptides. Reassess baseline GH, IGF-1, and GHRH receptor sensitivity.
- Week 17+: Repeat cycle or switch to no-DAC protocol for pulsatile maintenance.
Who Should Choose CJC-1295 with DAC?
Ideal candidates:
- IGF-1 maximization. If your primary goal is to elevate serum IGF-1 for anabolism, immune function, and metabolic health, DAC's sustained GH elevation is superior to pulsatile dosing. IGF-1 responds to 24-hour integrated GH exposure, not peak GH.
- Convenience and compliance. One injection per week (vs. 2-3 daily) is dramatically easier to remember and execute. Users with irregular schedules or traveling frequently benefit from this simplicity.
- Stable GH elevation for lean-mass protocols. Although pulsatile GH is superior for lipolysis, sustained IGF-1 elevation drives protein synthesis and satellite cell recruitment. If your goal is muscle hypertrophy (not fat loss), DAC is preferable.
- Older users or those with blunted GH axis. Individuals 50+ with age-related GH decline often respond well to sustained GHRH agonism because their endogenous GH secretion is already blunted. Preserving sleep-GH is less critical if baseline sleep-GH is already minimal.
- Cost-conscious users. DAC is injected less frequently, reducing total injection volume and potentially lowering peptide costs per cycle (though individual peptide cost may be higher).
Safety Profile
CJC-1295 with DAC is generally well-tolerated but requires more monitoring than no-DAC due to prolonged exposure:
- Common side effects: Flushing, lightheadedness, headache (especially after first 1-2 injections during accumulation). Injection-site reactions (mild, localized).
- IGF-1 elevation risk: Because DAC creates sustained GH elevation, IGF-1 rises more dramatically and persistently. Excessive IGF-1 (>1.5x upper reference limit sustained) is associated with:
- Joint pain and stiffness (especially knees, shoulders).
- Carpal tunnel syndrome (nerve compression from tissue swelling).
- Hypertension (GH and IGF-1 both raise BP slightly).
- Theoretical cancer risk (growth factors accelerate cell division; long-term data are limited).
- Monitoring protocol: Check fasting IGF-1 levels every 4 weeks during the first 12 weeks (to catch rapid rises), then every 8 weeks. Target: IGF-1 <1.3x upper reference limit. If IGF-1 exceeds this, reduce dose or extend interval to every 10 days.
- Pituitary desensitization: After 8-12 weeks, GH response per unit of CJC-1295 DAC declines (normal adaptation). This is why cycling (12 weeks on, 4-8 weeks off) is recommended—off-periods allow GHRH receptor sensitization to recover.
- Contraindications: Avoid with active malignancy, untreated sleep apnea (GH worsens apnea severity), or severe carpal tunnel syndrome. Caution in users with IGF-1-sensitive cancers or conditions.
- Blood pressure and glucose: GH raises both modestly. Monitor monthly if using concurrent vasoconstrictive agents or insulin.
Comparison: DAC vs. No-DAC at a Glance
- Half-life: DAC = 6-8 days; No-DAC = ~30 min.
- Injection frequency: DAC = 1x/week; No-DAC = 2-3x/day.
- GH profile: DAC = sustained; No-DAC = pulsatile.
- Sleep-GH: DAC = suppressed; No-DAC = preserved.
- IGF-1 elevation: DAC = maximal (stable); No-DAC = moderate (pulsatile-dependent).
- Pituitary sensitivity: DAC = desensitization after 8-12 weeks; No-DAC = preserved long-term.
- Best for: DAC = convenience + anabolism; No-DAC = pulsatility + sleep GH + long-term axis health.
CJC-1295 with DAC, when paired with daily Ipamorelin and monitored for IGF-1 elevation, offers a high-convenience, high-efficacy protocol for sustained GH axis stimulation and anabolic outcomes over 12-week cycles.